

December 4, 2023

To the creditors of Immunovaccine Technologies Inc.

On November 29, 2023, Immunovaccine Technologies Inc. was declared bankrupt and the undersigned FTI Consulting Canada Inc. was appointed as Trustee, for additional information please refer to the website <http://cfcanada.fticonsulting.com/imv/>

In accordance with statutory requirements of the Bankruptcy and Insolvency Act you are receiving this Notice to Creditors along with the following documents:

1. The statutory Notice to Creditors of First Meeting
2. Certificate of Appointment from the Official Receiver
3. Statement of Affairs
4. Listing of Creditors
5. Proxy

On November 29, 2023, the Court granted an Order (the “CCAA Termination Order”). Pursuant to Paragraph 16 of the CCAA Termination order, granting the Applicants or the Monitor on their behalf, the authority to authorize Immunovaccine Technologies Inc. to make an assignment in bankruptcy under the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3, as amended (the “BIA”). FTI Consulting Canada Inc. (“FTI”) was authorized to act as trustee in bankruptcy.

On September 27, 2023, the Court granted an Order (the “Amended ARIO Order”), among other things, authorize the Monitor and the Applicants to stop processing claims. the Monitor and the Applicants are dispensed from further obligations to review Proof of Claim filed in the Claims Process, and dispensed from value the amount and terms set out therein for voting and distribution purposes. Pursuant to Paragraph 18 of the Order, the Trustee appointed is not required to (i) commence a further claims process; (ii) accept proofs of claim pursuant to section 124 of the BIA; or (iii) make any determinations with respect to claims pursuant to section 135 of the BIA. Consequently, creditors are not required to file a proof of claim in the bankruptcy proceedings with the Trustee.

Please refer to the enclosed Statement of Affairs for details on assets and liabilities within the estate. The liabilities within the estate are based on the Immunovaccine Technologies Inc.’s books and records as of May 1, 2023, after deducting any secured creditor distribution pursuant to Initial Distribution Order on September 6, 2023. The Company has no remaining assets, and it is not anticipated that there will be any funds available to distribute to creditors in the bankruptcy.



Corporate Finance

TD South Tower
79 Wellington Street West
Suite 2010, P.O. Box 104
Toronto, ON M5K 1G8

T: 416.649.8100
F: 416.649.8101
fticonsulting.com

Any questions can be directed to the following contact at the Trustee's office:
Adsaran Vithiyananthan at 1-833-860-8353 (toll free), or by email at imv@fticonsulting.com

Sincerely,


FTI Consulting Canada Inc.

In its capacity as Trustee of the estate of

Immunovaccine Technologies Inc.

and not in its personal or corporate capacity.

Per:



Jeffrey Rosenberg, Senior Managing Director
79 Wellington Street West | Suite 2010
Toronto, Ontario, M5K 1G8



Industry Canada
Office of the Superintendent
of Bankruptcy Canada

Industrie Canada
Bureau du surintendant
des faillites Canada

District of: Ontario
Division No.: 09 - Toronto
Court No.: 31-3017180
Estate No.: 31-3017180

In the Matter of the Bankruptcy of:

Immunovaccine Technologies Inc.

Debtor

FTI CONSULTING CANADA INC.

Licensed Insolvency Trustee

Ordinary Administration

Date and time of bankruptcy:	December 01, 2023, 13:25	Security:	\$0.00
Date of trustee appointment:	December 01, 2023		
Meeting of creditors:	December 12, 2023, 13:00 MS Teams: 292093398899 Code: iEhHDB 79 Wellington St W, Suite 2010 Dial:866-840-8976 ID:343286689, Ontario Canada,		
Chair:	Trustee		

CERTIFICATE OF APPOINTMENT - Section 49 of the Act; Rule 85

I, the undersigned, official receiver in and for this bankruptcy district, do hereby certify that:

- the aforementioned debtor filed an assignment under section 49 of the *Bankruptcy and Insolvency Act*;
- the aforementioned trustee was duly appointed trustee of the estate of the debtor.

The said trustee is required:

- to provide to me, without delay, security in the aforementioned amount;
- to send to all creditors, within five days after the date of the trustee's appointment, a notice of the bankruptcy; and
- when applicable, to call in the prescribed manner a first meeting of creditors, to be held at the aforementioned time and place or at any other time and place that may be later requested by the official receiver.

Date: December 01, 2023, 13:33

E-File/Dépôt Electronique

Official Receiver

151 Yonge Street, 4th Floor, Toronto, Ontario, Canada, M5C2W7, (877)376-9902

Canada

District of:

Division No. -

Court No.

Estate No.

Original

Amended

-- Form 78 --

Statement of Affairs (Business Bankruptcy) made by an entity
(Subsection 49(2) and Paragraph 158(d) of the Act / Subsections 50(2) and 62(1) of the Act)

In the Matter of the Bankruptcy of
Immunovaccine Technologies Inc.
of the city of Toronto,
in the Province of Ontario

To the bankrupt:


You are required to carefully and accurately complete this form and the applicable attachments showing the state of your affairs on the date of the bankruptcy, on the 1st day of May 2023. When completed, this form and the applicable attachments will constitute the Statement of Affairs and must be verified by oath or solemn declaration.

LIABILITIES (as stated and estimated by the officer)	ASSETS (as stated and estimated by the officer)
1. Unsecured creditors as per list "A" 6,154,067.16	1. Inventory 0.00
Balance of secured claims as per list "B" 31,155,800.00	2. Trade fixtures, etc. 0.00
Total unsecured creditors 37,309,867.16	3. Accounts receivable and other receivables, as per list "E"
2. Secured creditors as per list "B" 0.00	Good 0.00
3. Preferred creditors as per list "C" 0.00	Doubtful 0.00
4. Contingent, trust claims or other liabilities as per list "D"	Bad 0.00
estimated to be reclaimable for 0.00	Estimated to produce 0.00
Total liabilities 37,309,867.16	4. Bills of exchange, promissory note, etc., as per list "F" ... 0.00
Surplus NIL	5. Deposits in financial institutions 0.00
	6. Cash 0.00
	7. Livestock 0.00
	8. Machinery, equipment and plant 0.00
	9. Real property or immovable as per list "G" 0.00
	10. Furniture 0.00
	11. RRSPs, RRIIFs, life insurance, etc. 0.00
	12. Securities (shares, bonds, debentures, etc.) 0.00
	13. Interests under wills 0.00
	14. Vehicles 0.00
	15. Other property, as per list "H" 0.00
	If bankrupt is a corporation, add:
	Amount of subscribed capital 0.00
	Amount paid on capital 0.00
	Balance subscribed and unpaid 0.00
	Estimated to produce 0.00
	Total assets 0.00
	Deficiency 37,309,867.16

I, Jeffrey Rosenberg, of the city of Toronto in the Province of Ontario, do swear (or solemnly declare) that this statement and the attached lists are to the best of my knowledge, a full, true and complete statement of the affairs of the Corporation on the 30th day of November 2023 and fully disclose all property of every description that is in my possession or that may devolve on me in accordance with the Act.

SWORN (or SOLEMNLY DECLARED)

before me at the city of Toronto in the Province of Ontario, on this 30th day of November 2023.

DocuSigned by:

1495FFA3CAEC437

A commissioner of oaths | LSO#80200N

DS


Jeffrey Rosenberg
Senior Managing Director,
FTI Consulting Canada Inc., solely in its
capacity as Court-appointed Monitor of
Immunovaccine Technologies Inc.,
pursuant to its powers outlined in
the Amended ARIO Order and
the CCAA Termination Order,
and not in its personal or corporate capacity

In the Matters of the Bankrupt of Immunovaccine Technologies Inc.
List of Creditors
Estate # 31-3017180

Notes:

1. The liabilities within the estate are based on the Immunovaccine Technologies Inc.'s books and records as of May 1, 2023, after deducting any secured creditor distribution pursuant to Initial Distribution Order on September 6, 2023.
2. All US\$ dollar amounts are converted to CA\$ dollar amounts using US\$ 1.0000/CA\$ 1.3546, using the Bank of Canada interest rate on May 1, 2023, the date of the initial insolvency event when Immunovaccine Technologies Inc. sought and obtained the initial order under the the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA").

Creditor Name	Amount (USD)	Amount (CAD)
Agilent Technologies Canada Inc.	1,760	2,384
Anton Paar Canada Inc.	1,563	2,117
ARENSIA Exploratory Medicine GmbH	153,778	208,308
Atlantic Canada Opportunities Agency	-	-
Baker Tilly Nova Scotia	6,500	8,805
Bay Area Health Trust	10,957	14,842
Becton Dickinson Canada Inc.	46,631	63,167
Biolegend, Inc.	37,742	51,125
BioNova	2,932	3,972
BioRender	21,804	29,536
BioSpring GmbH	141,989	192,338
Brittany Myers	-	-
Business Wire Canada Ltd.	10,579	14,331
Cagene bioPharma, LLC (dba Emergent BioSolutions)	337,240	456,826
Cambridge Environmental Products Inc.	156	211
Canada Revenue Agency	-	-
Carmichael Engineering Ltd.	716	969
Cedarlane Corporation	4,766	6,456
Centre Hospitalier de l'Université de Montréal	17,862	24,196
Ceridian HCM Inc.	98	133
Chondrex, Inc.	4,341	5,880
CHU de Quebec - Universite Laval	157,397	213,211
Chubb Life Insurance Company of Canada	120	163
Cintas Halifax	655	887
Clinigen Clinical Supplies Management GmbH	188,623	255,509
Clinigen Clinical Supplies Management Inc.	61,786	83,695
Cole-Parmer Canada Company	295	399
Computershare Trust Company of Canada	3,413	4,623
Con-Test (A Division of Contamination Containment Technology Inc.)	3,302	4,473
Cox & Palmer	210	285
CPA Global (Ipan) LLC	26,909	36,451
Cromed Research S.R.L.	19,261	26,090
CTL Analyzers LLC	6,452	8,740
Curia Global, Inc.	36,844	49,908
Dalhousie University	33,650	45,582
Dalhousie University (c/o Department of Psychology)	912	1,236
Department of the Treasury Internal Revenue Service	-	-
Discovery Life Sciences	11,040	14,955
DSO Consulting LLC	40,950	55,471
Egret Clinical Research & Consulting	7,967	10,792
Equisolve, Inc.	3,009	4,075
Ethics Committee of Serbia	-	-
European Medicines Agency	-	-
Eve Technologies Corporation	3,001	4,065
FedEx Freight Canada Corporation	822	1,113
Fisher Scientific Company	7,153	9,689
Florida Department of Revenue	-	-
GenScript USA Inc.	470	637
Georgia Department of Revenue	-	-
Georgia Ministry of Health	-	-
GFL Environmental Services Inc.	1,103	1,494

In the Matters of the Bankrupt of Immunovaccine Technologies Inc.
List of Creditors
Estate # 31-3017180

Notes:

1. The liabilities within the estate are based on the Immunovaccine Technologies Inc.'s books and records as of May 1, 2023, after deducting any secured creditor distribution pursuant to Initial Distribution Order on September 6, 2023.
2. All US\$ dollar amounts are converted to CA\$ dollar amounts using US\$ 1.0000/CA\$ 1.3546, using the Bank of Canada interest rate on May 1, 2023, the date of the initial insolvency event when Immunovaccine Technologies Inc. sought and obtained the initial order under the the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA").

Creditor Name	Amount (USD)	Amount (CAD)
Glenwood Consulting Group Inc.	626	848
Halloran Consulting Group, Inc.	6,900	9,347
Health Canada	-	-
Horizon Credit II LLC	85,938	116,411
Horizon Funding I LLC	114,583	155,215
Horizon Technology Finance Corporation	15,500,000	20,996,300
Immudex USA	10,657	14,435
Indigo Parc Canada	392	531
Inkblot Technologies Inc.	3,425	4,639
Institut Pasteur	10,252	13,888
Interweigh Systems Inc.	281	381
Investment Quebec	18,400	24,924
Iron Mountain Canada Operations ULC	456	618
Kaleidoscope Data Privacy Consultants SL	11,114	15,055
Kuehne + Nagel Ltd.	300	407
La Clinique Du Copieur	3	4
Labcorp Drug Development Inc.	23,000	31,156
Land & Sea Instrumentation Ltd.	456	618
Latham & Watkins LLP	10,114	13,700
Leica Microsystems Canada	3,488	4,725
LifeSci Advisors, LLC	1,479	2,004
Linde Canada Inc.	2,425	3,285
Lindsay Construction Limited	11,460	15,524
Lyophilization Services of New England Inc.	63,988	86,677
Malvern Panalytical	667	903
Maritime Coffee	324	439
Massachusetts Department of Revenue	-	-
Matthew Matasar	6,000	8,128
McCarthy Tétrault LLP	134,873	182,699
McDougall Scientific Ltd.	6,209	8,410
Medair Time Critical Express Ltd.	1,458	1,975
Medic Delivery Services Limited	337	457
Medical Mart Supplies Ltd.	153	208
Medicines and Healthcare products Regulatory Agency	-	-
Millipore Canada Ltd.	2,807	3,802
Miltenyi Biotec, Inc.	819	1,109
NanoString Technologies, Inc.	19,947	27,020
NeoGenomics Laboratories Inc.	5,400	7,315
New Jersey Department of the Treasury Division of Taxation	-	-
New Zealand Health and Disability Ethics Committee Ministry of Health	-	-
Nova Scotia Health Authority	155	210
Novotech Australia Pty Ltd	54,407	73,699
Nucro-Technics	22,231	30,115
NYU Grossman School of Medicine	64,051	86,763
Ocala Oncology Center PL	20,300	27,498
Office of the Superintendent of Bankruptcy	-	-
Pan American Center for Oncology Trials, LLC	24,093	32,636
Payscale, Inc.	6,739	9,129
Pennsylvania Department of Revenue	-	-
Plant Care	150	204
Polypeptide Laboratories San Diego	80,600	109,181

In the Matters of the Bankrupt of Immunovaccine Technologies Inc.
List of Creditors
Estate # 31-3017180

Notes:

1. The liabilities within the estate are based on the Immunovaccine Technologies Inc.'s books and records as of May 1, 2023, after deducting any secured creditor distribution pursuant to Initial Distribution Order on September 6, 2023.
2. All US\$ dollar amounts are converted to CA\$ dollar amounts using US\$ 1.0000/CA\$ 1.3546, using the Bank of Canada interest rate on May 1, 2023, the date of the initial insolvency event when Immunovaccine Technologies Inc. sought and obtained the initial order under the the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA").

Creditor Name	Amount (USD)	Amount (CAD)
Powerscourt Investments XXV Trust	85,938	116,411
Powerscourt Investments XXV, LP	7,500,000	10,159,500
Precision for Medicine and Oncology Canada, Inc.	922,957	1,250,237
PriceWaterhouseCoopers LLP	248,225	336,245
ProRegulatory Biosciences Ltd.	13,117	17,768
Providence Portland Medical Center	103,037	139,574
Pylon Electronics	83	113
Q Squared Solutions Expression Analysis LLC	57,127	77,384
Reitbauer GmbH	2,116	2,867
Research Support Services, Monash Health	-	-
Revenu Québec	-	-
RingCentral, Inc.	2,859	3,873
ScienTek Software Inc.	10,000	13,546
SecureDocs	2,000	2,709
Services Linguistiques Versacom Inc.	3,418	4,630
Sheridan Road Advisors, LLC	1,104	1,495
Sigma-Aldrich Canada Ltd.	5,435	7,362
Smart & Biggar LLP	95,473	129,328
Solium Capital Inc.	2,542	3,443
Stanford University	112,325	152,156
Staples Business Advantage (A Division of Staples Inc.)	1,034	1,400
Supercity Office Systems	776	1,051
Surrogate Technology Management Inc.	31,918	43,236
Synchrogenix – A Certara Company	3,652	4,947
The Printing House Ltd.	273	369
Theradex (Europe) Ltd.	121,096	164,036
TNC 120-140 Eileen Stubbs Ltd.	137,286	185,968
Tounsley Research, Inc.	16,085	21,789
Troutman Sanders LLP	36,360	49,254
U.S. Food and Drug Administration	-	-
Uline Canada Corporation	329	445
University Health Network	73,598	99,696
University of Oxford	173,438	234,939
University of Sherbrooke	411	556
Veeva Systems Inc.	13,800	18,693
VWR International Co.	1,952	2,644
Waters Limited	2,043	2,767
Waters Limited	-	-
WCG IRB, Inc.	414	561
WorkVivo Limited	12,656	17,144
TOTAL	\$ 27,543,088	\$ 37,309,867

District of: Ontario
Division No. 09 - Toronto
Court No. 31-3017180
Estate No. 31-3017180

- FORM 36 -
Proxy
(Subsection 102(2) and paragraphs 51(1)(e) and 66.15(3)(b) of the Act)

In the Matter of the Bankruptcy of
Immunovaccine Technologies Inc.
of the city of Toronto,
in the Province of Ontario

I, _____, of _____, a creditor in the above matter, hereby
appoint _____, of _____, to be my
proxyholder in the above matter, except as to the receipt of dividends, _____ (with or without) power to
appoint another proxyholder in his or her place.

Dated at _____, this _____ day of _____, _____.

Witness

Individual Creditor

Witness

Name of Corporate Creditor

Per _____
Name and Title of Signing Officer

Return To:

FTI Consulting Canada Inc. - Licensed Insolvency Trustee

TD Waterhouse Tower
79 Wellington St. West
Toronto ON M5K 1G8
Fax: (416) 649-8101